Aticaprant
As of the edition of 20 October 2026, Aticaprant is a small molecule: in active development; acts on OPRK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 17, 5 stopped early
- Disease areas
- Mental health; Nervous system; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRK1 | Kappa-type opioid receptor | P41145 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 5 | 1 | 1 |
| Phase 2 | 5 | 4 | 0 | 1 |
| Phase 3 | 5 | 2 | 0 | 3 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2010 to now |
| Johnson & Johnson | Lead sponsor of trials | 2015 to now |